BMY
BRISTOL MYERS SQUIBB CO
$57.13
+0.40%
$116.7B
No data for this timeframe.
Vol
Market Cap$116.7B
Cap SizeLarge Cap
Analyst ConsensusHold (39%)
Inst. Holders50 funds
Inst. Value$56.6B
Inst. Activity29 buys / 21 sells
Insider Activity0B / 1S
Insider Net $-$1.6M
Reddit Sentiment67° Warm
SEC Reports4
Recent Activity
Aug 17, 2026
fda_pdufa
PDUFA: BMY — iberdomide in relapsed or refractory multiple myeloma — 2026-08-17
FDA target action date 2026-08-17 for BMY (BRISTOL MYERS SQUIBB CO). Drug: iberdomide. Indication: r
Jun 3, 2026
Insider
Short Bartie Wendy surrendered for taxes 3,876 shares
EVP, Corporate Affairs @ $54.72 ($212.1K)
Jun 3, 2026
Insider
Short Bartie Wendy acquired via exercise 8,040 shares
EVP, Corporate Affairs
May 31, 2026
SEC
13 firms acted on BMY: RBC Capital, Barclays, UBS, B of A Securities, Guggenheim, Piper Sandler, Goldman Sachs, Jefferies, Wolfe Research, Leerink Partners, Citigroup, Bernstein, Barclays
ANALYST-UPGRADE — Impact 3/10
May 1, 2026
SEC
UBS upgrades BMY to Buy, PT $65 (+7%) — Mixed signals from high short interest and negative EPS revisions
ANALYST-UPGRADE — Impact 2/10
May 1, 2026
Insider
Lenkowsky Adam acquired via exercise 1,373 shares
EVP, Chief Commercial Officer
Apr 21, 2026
SEC
A federal court granted a motion to remand a civil case involving Bristol-Myers Squibb (BMY) back to New Jersey state co
COURT-RULING — Impact 3/10
Inst.
BANK OF AMERICA CORP — DOUBLED
32,586,981 shares ($2.0B)
Price Targets
$63.08
+10.4% upside
Buy
Current $57.13
Low $40.00
Median $65.00
High $75.00
25 analysts
$40.00
$75.00
Analyst Ratings
6Strong Buy
8Buy
20Hold
2Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Apr 9, 2026 | B of A Securities | MAINTAIN | Buy → Buy |
| Apr 8, 2026 | Guggenheim | REITERATE | Buy → Buy |
| Apr 8, 2026 | Cantor Fitzgerald | MAINTAIN | Neutral → Neutral |
| Mar 17, 2026 | HSBC | MAINTAIN | Hold → Hold |
| Feb 25, 2026 | RBC Capital | INITIATE | Sector Perform |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $1.61 | $1.48 — $1.71 | 10% YoY | 22 |
| Next Q | $1.60 | $1.51 — $1.69 | -2% YoY | 22 |
| Current FY | $6.31 | $6.05 — $6.54 | 3% YoY | 28 |
| Next FY | $6.17 | $5.43 — $6.95 | -2% YoY | 28 |
Latest Reports
BULLISH
ANALYST-UPGRADE
3/10
13 firms acted on BMY: RBC Capital, Barclays, UBS, B of A Securities, Guggenheim, Piper Sandler, Goldman Sachs, Jefferies, Wolfe Research, Leerink Partners, Citigroup, Bernstein, Barclays
May 31, 2026
MIXED
ANALYST-UPGRADE
2/10
UBS upgrades BMY to Buy, PT $65 (+7%) — Mixed signals from high short interest and negative EPS revisions
May 1, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| BlackRock, Inc. | $10.4B | — |
| VANGUARD CAPITAL MANAGEMENT LLC | $8.0B | — |
| STATE STREET CORP | $6.0B | — |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $3.7B | — |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $2.8B | — |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 3, 2026 | Short Bartie | F | $212.1K |
| Jun 3, 2026 | Short Bartie | M | $0.00 |
| May 1, 2026 | Lenkowsky Adam | M | $0.00 |
| May 1, 2026 | Lenkowsky Adam | J | $0.00 |
| May 1, 2026 | Lenkowsky Adam | F | $34.9K |
Reddit Sentiment
67°
Warm
Bearish
Neutral
Bullish
50 institutional holders with $56.6B total value (933,298,134 shares) as of 2026-Q1. Top holders: BlackRock,, VANGUARD, STATE. Net buying activity: 29 institutions added/increased vs 21 reduced.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 171,682,888 | $10.4B | 18.4% | — |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 132,320,240 | $8.0B | 14.2% | — |
| 3 | STATE STREET CORP | 98,564,914 | $6.0B | 10.6% | — |
| 4 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 61,115,373 | $3.7B | 6.6% | — |
| 5 | VANGUARD PORTFOLIO MANAGEMENT LLC | 46,230,155 | $2.8B | 5.0% | — |
| 6 | BANK OF AMERICA CORP /DE/ | 32,586,981 | $2.0B | 3.5% | DOUBLED +116.4% |
| 7 | MORGAN STANLEY | 29,198,554 | $1.8B | 3.1% | — |
| 8 | AMERIPRISE FINANCIAL INC | 26,470,718 | $1.6B | 2.8% | — |
| 9 | Independent Franchise Partners LLP | 21,275,474 | $1.3B | 2.3% | — |
| 10 | DIMENSIONAL FUND ADVISORS LP | 18,762,589 | $1.1B | 2.0% | — |
| 11 | PZENA INVESTMENT MANAGEMENT LLC | 17,095,731 | $1.0B | 1.8% | — |
| 12 | Legal & General Group Plc | 16,877,626 | $1.0B | 1.8% | — |
| 13 | Invesco Ltd. | 15,509,999 | $940.7M | 1.7% | — |
| 14 | GOLDMAN SACHS GROUP INC | 14,054,518 | $852.4M | 1.5% | — |
| 15 | SCHRODER INVESTMENT MANAGEMENT GROUP | 12,235,494 | $742.1M | 1.3% | — |
| 16 | TWO SIGMA INVESTMENTS, LP | 11,535,106 | $699.6M | 1.2% | — |
| 17 | VANGUARD FIDUCIARY TRUST CO | 11,517,204 | $698.5M | 1.2% | — |
| 18 | ROYAL BANK OF CANADA | 10,958,702 | $664.6M | 1.2% | — |
| 19 | FMR LLC | 10,671,103 | $647.2M | 1.1% | — |
| 20 | VICTORY CAPITAL MANAGEMENT INC | 9,151,211 | $555.0M | 1.0% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| BANK OF AMERICA CORP /DE/ | DOUBLED | 15,059,295 | 32,586,981 | +116.4% | $2.0B | 2026-Q1 |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | TRIM | 17,190,560 | 8,872,779 | -48.4% | $538.1M | 2026-Q1 |
| Capital International Investors | TRIM | 20,991,527 | 8,432,445 | -59.8% | $511.2M | 2026-Q1 |
| Allianz Asset Management GmbH | ADD | 5,495,386 | 6,879,864 | +25.2% | $417.3M | 2026-Q1 |
| FRANKLIN RESOURCES INC | TRIM | 8,551,157 | 6,198,167 | -27.5% | $375.9M | 2026-Q1 |
| DODGE & COX | TRIM | 7,078,250 | 4,622,820 | -34.7% | $280.4M | 2026-Q1 |
| MARSHALL WACE, LLP | TRIM | 10,844,270 | 3,689,838 | -66.0% | $223.8M | 2026-Q1 |
| Artemis Investment Management LLP | ADD | 1,740,753 | 2,885,298 | +65.7% | $175.0M | 2026-Q1 |
| Capital World Investors | NEW | — | 2,225,030 | — | $134.9M | 2026-Q1 |
| NATIXIS | ADD | 1,545,529 | 2,068,064 | +33.8% | $125.4M | 2026-Q1 |
| NORDEA INVESTMENT MANAGEMENT AB | DOUBLED | 200,318 | 2,033,068 | +914.9% | $121.9M | 2026-Q1 |
| Mariner, LLC | ADD | 1,344,888 | 1,744,281 | +29.7% | $105.8M | 2026-Q1 |
| PUBLIC SECTOR PENSION INVESTMENT BOARD | DOUBLED | 374,162 | 1,609,745 | +330.2% | $97.6M | 2026-Q1 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | DOUBLED | 433,169 | 1,466,671 | +238.6% | $89.0M | 2026-Q1 |
| MACKENZIE FINANCIAL CORP | ADD | 1,108,121 | 1,465,433 | +32.2% | $88.9M | 2026-Q1 |
| FIFTH THIRD BANCORP | DOUBLED | 566,644 | 1,191,379 | +110.3% | $72.3M | 2026-Q1 |
| DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main | TRIM | 2,081,079 | 1,163,953 | -44.1% | $70.6M | 2026-Q1 |
| Connor, Clark & Lunn Investment Management Ltd. | NEW | — | 1,100,589 | — | $66.8M | 2026-Q1 |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | ADD | 768,040 | 1,050,815 | +36.8% | $64.3M | 2026-Q1 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 2,353,689 | 977,051 | -58.5% | $59.3M | 2026-Q1 |
| PINEBRIDGE INVESTMENTS LLC | ADD | 686,189 | 933,316 | +36.0% | $56.6M | 2026-Q1 |
| TORONTO DOMINION BANK | TRIM | 1,340,511 | 909,773 | -32.1% | $55.2M | 2026-Q1 |
| M&T BANK CORP | DOUBLED | 51,961 | 771,822 | +1385.4% | $46.8M | 2026-Q1 |
| Tredje AP-fonden | NEW | — | 604,075 | — | $36.6M | 2026-Q1 |
| EXCHANGE TRADED CONCEPTS, LLC | DOUBLED | 116,233 | 560,618 | +382.3% | $34.0M | 2026-Q1 |
16 unique insiders with 50 transactions. Net insider value: -$1.6M ($0.00 bought, $1.6M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 3, 2026 | Short Bartie Wendy | EVP, Corporate Affairs | TAX W/H | 3,876 | $54.72 | $212.1K |
| Jun 3, 2026 | Short Bartie Wendy | EVP, Corporate Affairs | EXERCISE | 8,040 | — | — |
| May 1, 2026 | Lenkowsky Adam | EVP, Chief Commercial Officer | EXERCISE | 1,373 | — | — |
| May 1, 2026 | Lenkowsky Adam | EVP, Chief Commercial Officer | J | 203 | — | — |
| May 1, 2026 | Lenkowsky Adam | EVP, Chief Commercial Officer | TAX W/H | 599 | $58.22 | $34.9K |
| Apr 1, 2026 | Elkins David V | EVP, Chief Financial Officer | SELL | 25,519 | $61.60 | $1.6M |
| Apr 1, 2026 | Shanahan Karin | EVP, Chief Supply Chain & Ops | TAX W/H | 1,692 | $61.73 | $104.4K |
| Apr 1, 2026 | Shanahan Karin | EVP, Chief Supply Chain & Ops | EXERCISE | 3,307 | — | — |
| Mar 31, 2026 | McMullen Michael R. | Director | AWARD | 577.082 | $60.65 | $35.0K |
| Mar 31, 2026 | Arduini Peter J | Director | AWARD | 577.082 | $60.65 | $35.0K |
| Mar 31, 2026 | Rice Derica W | Director | AWARD | 638.912 | $60.65 | $38.8K |
| Mar 31, 2026 | Samuels Theodore R. II | Director | AWARD | 845.012 | $60.65 | $51.2K |
| Mar 31, 2026 | YALE PHYLLIS R | Director | AWARD | 577.082 | $60.65 | $35.0K |
| Mar 10, 2026 | Elkins David V | EVP, Chief Financial Officer | TAX W/H | 2,883 | $60.13 | $173.4K |
| Mar 10, 2026 | Elkins David V | EVP, Chief Financial Officer | AWARD | 52,898 | — | — |
| Mar 10, 2026 | Gallman Cari | EVP, General Counsel | J | 102 | — | — |
| Mar 10, 2026 | Gallman Cari | EVP, General Counsel | TAX W/H | 415 | $60.13 | $25.0K |
| Mar 10, 2026 | Gallman Cari | EVP, General Counsel | EXERCISE | 5,201 | — | — |
| Mar 10, 2026 | Lenkowsky Adam | EVP, Chief Commercial Officer | TAX W/H | 831 | $60.13 | $50.0K |
| Mar 10, 2026 | Meyers Gregory Scott | EVP, Chief Digital & Tech Off. | EXERCISE | 19,760 | — | — |
| Mar 10, 2026 | Lenkowsky Adam | EVP, Chief Commercial Officer | AWARD | 32,653 | — | — |
| Mar 10, 2026 | Meyers Gregory Scott | EVP, Chief Digital & Tech Off. | EXERCISE | 2,839 | — | — |
| Mar 10, 2026 | Plenge Robert M | EVP, Chief Research Officer | EXERCISE | 1,107 | — | — |
| Mar 10, 2026 | Plenge Robert M | EVP, Chief Research Officer | J | 124 | — | — |
| Mar 10, 2026 | Shanahan Karin | EVP, Chief Supply Chain & Ops | TAX W/H | 1,112 | $60.13 | $66.9K |
| Mar 10, 2026 | Short Bartie Wendy | EVP, Corporate Affairs | TAX W/H | 205 | $60.13 | $12.3K |
| Mar 10, 2026 | Shanahan Karin | EVP, Chief Supply Chain & Ops | EXERCISE | 19,760 | — | — |
| Mar 10, 2026 | Shibutani Hiroshi Chris | EVP, Chief Strategy Officer | AWARD | 11,755 | — | — |
| Mar 10, 2026 | Shanahan Karin | EVP, Chief Supply Chain & Ops | AWARD | 21,224 | — | — |
| Mar 10, 2026 | Shanahan Karin | EVP, Chief Supply Chain & Ops | AWARD | 31,837 | — | — |
| Mar 10, 2026 | BOERNER CHRISTOPHER S. | Chief Executive Officer | J | 743 | — | — |
| Mar 10, 2026 | BOERNER CHRISTOPHER S. | Chief Executive Officer | EXERCISE | 6,618 | — | — |
| Mar 10, 2026 | BOERNER CHRISTOPHER S. | Chief Executive Officer | TAX W/H | 3,006 | $60.13 | $180.8K |
| Mar 10, 2026 | BOERNER CHRISTOPHER S. | Chief Executive Officer | EXERCISE | 40,398 | — | — |
| Mar 10, 2026 | BOERNER CHRISTOPHER S. | Chief Executive Officer | AWARD | 104,490 | — | — |
| Mar 10, 2026 | BOERNER CHRISTOPHER S. | Chief Executive Officer | AWARD | 156,735 | — | — |
| Mar 10, 2026 | Elkins David V | EVP, Chief Financial Officer | J | 860 | — | — |
| Mar 10, 2026 | Elkins David V | EVP, Chief Financial Officer | AWARD | 35,265 | — | — |
| Mar 10, 2026 | Elkins David V | EVP, Chief Financial Officer | EXERCISE | 47,424 | — | — |
| Mar 10, 2026 | Elkins David V | EVP, Chief Financial Officer | EXERCISE | 7,654 | — | — |
| Mar 10, 2026 | Massacesi Cristian | EVP,Chief Med Offr,Head of Dev | AWARD | 26,122 | — | — |
| Mar 10, 2026 | Massacesi Cristian | EVP,Chief Med Offr,Head of Dev | AWARD | 39,184 | — | — |
| Mar 10, 2026 | Shibutani Hiroshi Chris | EVP, Chief Strategy Officer | AWARD | 7,837 | — | — |
| Mar 10, 2026 | Short Bartie Wendy | EVP, Corporate Affairs | AWARD | 6,531 | — | — |
| Mar 10, 2026 | Short Bartie Wendy | EVP, Corporate Affairs | J | 72 | — | — |
| Mar 10, 2026 | Short Bartie Wendy | EVP, Corporate Affairs | EXERCISE | 4,495 | — | — |
| Mar 10, 2026 | Short Bartie Wendy | EVP, Corporate Affairs | EXERCISE | 639 | — | — |
| Mar 10, 2026 | Short Bartie Wendy | EVP, Corporate Affairs | AWARD | 9,796 | — | — |
| Mar 10, 2026 | Holzer Phil M | SVP and Controller | EXERCISE | 4,612 | — | — |
| Mar 10, 2026 | Holzer Phil M | SVP and Controller | EXERCISE | 811 | — | — |
4 SEC filing reports analyzed. Sentiment: 1 bullish, 0 bearish, 1 mixed, 2 neutral. Avg impact: 2.8/10.
MIXED
ANALYST-UPGRADE
2/10
UBS upgrades BMY to Buy, PT $65 (+7%) — Mixed signals from high short interest and negative EPS revisions
May 1, 2026
BULLISH
ANALYST-UPGRADE
3/10
13 firms acted on BMY: RBC Capital, Barclays, UBS, B of A Securities, Guggenheim, Piper Sandler, Goldman Sachs, Jefferies, Wolfe Research, Leerink Partners, Citigroup, Bernstein, Barclays
May 31, 2026
NEUTRAL
COURT-RULING
3/10
A federal court granted a motion to remand a civil case involving Bristol-Myers Squibb (BMY) back to
Apr 21, 2026
NEUTRAL
DEFA14A
3/10
Bristol-Myers Squibb Co filed a definitive proxy statement (DEFA14A) for its 2026 Annual Meeting. Th
Mar 25, 2026
No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.
Current analyst consensus: Sell (39% buy). Based on 36 analysts: 6 strong buy, 8 buy, 20 hold, 2 sell, 0 strong sell.
Analyst Price Targets
$63.08 mean target
+10.4% upside
Buy (2.52)
$40.00 Low
$75.00 High
| Metric | Value |
|---|---|
| Current Price | $57.13 |
| Target Low | $40.00 |
| Target Mean | $63.08 |
| Target Median | $65.00 |
| Target High | $75.00 |
| # Analysts | 25 |
| Recommendation | Buy (2.52) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$1.61 | $1.48 | $1.71 | 10.0% | +0.1% | 0↑ 3↓ | $11.7B | -4.6% | 22 |
| Next Q 2026-09-30 |
$1.60 | $1.51 | $1.69 | -1.7% | +0.2% | 2↑ 2↓ | $12.0B | -1.7% | 22 |
| Current FY 2026-12-31 |
$6.31 | $6.05 | $6.54 | 2.6% | -0.1% | 6↑ 1↓ | $47.3B | -1.8% | 28 |
| Next FY 2027-12-31 |
$6.17 | $5.43 | $6.95 | -2.3% | +0.2% | 5↑ 3↓ | $46.2B | -2.3% | 28 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $1.607 | |
| 7d ago | $1.611 | -0.005 |
| 30d ago | $1.605 | +0.001 |
| 60d ago | $1.665 | -0.058 |
| 90d ago | $1.665 | -0.058 |
12 analyst firms have rated this stock: 1 upgrades, 0 downgrades, 2 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Apr 9, 2026 | B of A Securities | MAINTAIN | Buy | Buy |
| Apr 8, 2026 | Guggenheim | REITERATE | Buy | Buy |
| Apr 8, 2026 | Cantor Fitzgerald | MAINTAIN | Neutral | Neutral |
| Mar 17, 2026 | HSBC | MAINTAIN | Hold | Hold |
| Feb 25, 2026 | RBC Capital | INITIATE | — | Sector Perform |
| Feb 23, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Feb 20, 2026 | Barclays | INITIATE | — | Overweight |
| Feb 6, 2026 | Citigroup | MAINTAIN | Neutral | Neutral |
| Feb 6, 2026 | Wells Fargo | MAINTAIN | Equal-Weight | Equal-Weight |
| Feb 6, 2026 | Guggenheim | MAINTAIN | Buy | Buy |
| Jan 28, 2026 | Piper Sandler | MAINTAIN | Overweight | Overweight |
| Jan 27, 2026 | Citigroup | MAINTAIN | Neutral | Neutral |
| Jan 13, 2026 | Leerink Partners | MAINTAIN | Outperform | Outperform |
| Jan 9, 2026 | Scotiabank | MAINTAIN | Sector Perform | Sector Perform |
| Jan 7, 2026 | Citigroup | MAINTAIN | Neutral | Neutral |
| Jan 7, 2026 | UBS | UPGRADE | Neutral | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 6 | 8 | 20 | 2 | 0 | 39% | |
| May 1, 2026 | 6 | 9 | 19 | 2 | 0 | 42% | |
| Apr 1, 2026 | 6 | 9 | 19 | 2 | 0 | 42% | |
| Mar 1, 2026 | 6 | 9 | 19 | 2 | 0 | 42% | |
| Feb 1, 2026 | 6 | 8 | 18 | 2 | 0 | 41% | |
| Jan 1, 2026 | 6 | 7 | 19 | 2 | 0 | 38% | |
| Dec 1, 2025 | 4 | 7 | 21 | 2 | 0 | 32% | |
| Nov 1, 2025 | 4 | 7 | 20 | 2 | 0 | 33% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
67°
Warm
Bearish
Neutral
Bullish
2 mentions
2 bullish
0 bearish
2 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| Mar 3, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| Mar 3, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
Aug 17, 2026
fda_pdufa
PDUFA: BMY — iberdomide in relapsed or refractory multiple myeloma — 2026-08-17
FDA target action date 2026-08-17 for BMY (BRISTOL MYERS SQUIBB CO). Drug: iberdomide. Indication: relapsed or refractory multiple myeloma. FDA accept
Jul 30, 2026
earnings_calendar
BMY Q2 2026 Earnings After Market Close — 2026-07-30
EPS est: $1.68 | Rev est: $12.0B
Jun 13, 2026
Clinical Trial
Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma
Phase Phase 2 — COMPLETED
Jun 13, 2026
Clinical Trial
Efficacy and Safety of Oral Azacitidine (CC-486) Compared to Investigator's Choice Therapy in Patients With Relapsed or Refractory Angioimmunoblastic T Cell Lymphoma
Phase Phase 3 — COMPLETED
Jun 12, 2026
Clinical Trial
Neoadjuvant Nivolumab Combination Treatment in Resectable Non-small Cell Lung Cancer Patients
Phase Phase 2 — COMPLETED
Jun 11, 2026
Clinical Trial
Nivolumab for Recurrent or Progressive IDH Mutant Gliomas
Phase Phase 2 — COMPLETED
Jun 11, 2026
Clinical Trial
RegoNivo vs Standard of Care Chemotherapy in AGOC
Phase Phase 3 — COMPLETED
Jun 4, 2026
short_volume
Short Volume: BMY — 57.5% short (1.8M / 3.1M)
Short: 1,794,536 | Exempt: 3,401 | TRF Vol: 3,123,175 | Short Ratio: 57.5% | Off-exchange volume (dark pool + OTC)
Jun 3, 2026
short_volume
Short Volume: BMY — 60.4% short (2.3M / 3.9M)
Short: 2,341,781 | Exempt: 128 | TRF Vol: 3,878,155 | Short Ratio: 60.4% | Off-exchange volume (dark pool + OTC)
Jun 1, 2026
short_volume
Short Volume: BMY — 66.0% short (4.2M / 6.3M)
Short: 4,177,588 | Exempt: 33,461 | TRF Vol: 6,328,361 | Short Ratio: 66.0% | Off-exchange volume (dark pool + OTC)
May 29, 2026
short_volume
Short Volume: BMY — 56.2% short (2.6M / 4.6M)
Short: 2,573,293 | Exempt: 3,606 | TRF Vol: 4,577,650 | Short Ratio: 56.2% | Off-exchange volume (dark pool + OTC)
May 27, 2026
short_volume
Short Volume: BMY — 61.5% short (1.7M / 2.8M)
Short: 1,736,232 | Exempt: 7,676 | TRF Vol: 2,823,814 | Short Ratio: 61.5% | Off-exchange volume (dark pool + OTC)
May 18, 2026
short_volume
Short Volume: BMY — 56.7% short (2.2M / 3.9M)
Short: 2,206,845 | Exempt: 3,133 | TRF Vol: 3,891,054 | Short Ratio: 56.7% | Off-exchange volume (dark pool + OTC)
May 18, 2026
dark_pool
Dark Pool: BMY — 8.5M shares, 129,247 trades
Week starting 2026-05-18. Total ATS volume: 8,513,596 shares across 129,247 trades.
May 15, 2026
clinical_trial_readout
Results Pending: Elotuzumab (Phase 2) — Completed 81d ago
Trial: Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab
Sponsor: Bristol-Myers Squibb
Phase: P
May 15, 2026
short_volume
Short Volume: BMY — 65.8% short (2.0M / 3.1M)
Short: 2,014,638 | Exempt: 2,796 | TRF Vol: 3,062,304 | Short Ratio: 65.8% | Off-exchange volume (dark pool + OTC)
May 11, 2026
dark_pool
Dark Pool: BMY — 9.0M shares, 138,582 trades
Week starting 2026-05-11. Total ATS volume: 8,994,429 shares across 138,582 trades.
May 4, 2026
clinical_trial_readout
T-90d Trial Readout: Adagrasib (Phase 2)
Trial: Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
Sponsor: Mirati Therapeutics Inc.
Phase: Phase 2 | Status:
May 4, 2026
dark_pool
Dark Pool: BMY — 9.9M shares, 142,822 trades
Week starting 2026-05-04. Total ATS volume: 9,913,249 shares across 142,822 trades.
May 1, 2026
clinical_trial_readout
T-90d Trial Readout: Adagrasib (Phase 2)
Trial: Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)
Sponsor: Mirati Therapeutics Inc.
Phase: Phase 2 | Status:
Mar 30, 2026
Enforcement
1:24-cv-06924 CenterWell Pharmacy, Inc.v. Celgene Corporation et al
Court ruling from United States District Court for the Southern District of New York. Docket: N/A
Mar 30, 2026
Enforcement
1:23-cv-07871 Louisiana Health Service & Indemnity Company et al v. Celgene Corporation et al
Court ruling from United States District Court for the Southern District of New York. Docket: N/A
Mar 30, 2026
Enforcement
1:24-cv-02230 New York Hotel Trades Council & Hotel Association of New York City, Inc. Health Benefits Fund v. Celgene Corporation et al
Court ruling from United States District Court for the Southern District of New York. Docket: N/A
Mar 25, 2026
FDA
KRAZATI
Supplemental Approval — Labeling — ADAGRASIB — TABLET — ORAL
Mar 25, 2026
FDA
KRAZATI
Supplemental Approval — Labeling — ADAGRASIB — TABLET — ORAL